Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

全面介绍

书目详细资料
Main Authors: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
格式: 文件
语言:English
出版: Elsevier 2023-08-01
丛编:Journal of Allergy and Clinical Immunology: Global
主题:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
在线阅读:http://www.sciencedirect.com/science/article/pii/S277282932300053X

因特网

http://www.sciencedirect.com/science/article/pii/S277282932300053X

相似书籍